SARS-CoV-2 Is More Efficient than HCoV-NL63 in Infecting a Small Subpopulation of ACE2+ Human Respiratory Epithelial Cells

Viruses. 2023 Mar 13;15(3):736. doi: 10.3390/v15030736.

Abstract

Human coronavirus (HCoV)-NL63 is an important contributor to upper and lower respiratory tract infections, mainly in children, while severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, can cause lower respiratory tract infections, and more severe, respiratory and systemic disease, which leads to fatal consequences in many cases. Using microscopy, immunohistochemistry (IHC), virus-binding assay, reverse transcriptase qPCR (RT-qPCR) assay, and flow cytometry, we compared the characteristics of the susceptibility, replication dynamics, and morphogenesis of HCoV-NL63 and SARS-CoV-2 in monolayer cultures of primary human respiratory epithelial cells (HRECs). Less than 10% HRECs expressed ACE2, and SARS-CoV-2 seemed much more efficient than HCoV-NL63 at infecting the very small proportion of HRECs expressing the ACE2 receptors. Furthermore, SARS-CoV-2 replicated more efficiently than HCoV-NL63 in HREC, which correlates with the cumulative evidence of the differences in their transmissibility.

Keywords: ACE2; Alphacoronavirus; Betacoronavirus; COVID-19; HCoV-NL63; SARS-CoV-2; human respiratory epithelial cells.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • COVID-19
  • Cell Line
  • Coronavirus NL63, Human* / pathogenicity
  • Epithelial Cells* / virology
  • Humans
  • Respiratory Tract Infections
  • SARS-CoV-2* / pathogenicity

Substances

  • Angiotensin-Converting Enzyme 2

Grants and funding

This research received no external funding.